{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:49:55Z","timestamp":1792658995785,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/ki.2011.502","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T13:49:01Z","timestamp":1329313741000},"page":"1067-1074","source":"Crossref","is-referenced-by-count":94,"title":["Proteasome inhibitor-based therapy for antibody-mediated rejection"],"prefix":"10.1016","volume":"81","author":[{"given":"R.","family":"Carlin Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita R.","family":"Alloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin L.","family":"Girnita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Steve Woodle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2011.502_bb0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0b013e3181b11b72","article-title":"HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss","volume":"88","author":"Lee","year":"2009","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0020","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1600-6143.2006.01711.x","article-title":"Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study","volume":"7","author":"Mao","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","article-title":"The effect of desensitization protocols on human splenic B-cell populations in vivo","volume":"7","author":"Ramos","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0040","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0045","doi-asserted-by":"crossref","first-page":"22123","DOI":"10.1074\/jbc.274.32.22123","article-title":"The proteasome, a novel protease regulated by multiple mechanisms","volume":"274","author":"DeMartino","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2011.502_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/ki.2011.502_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0161-5890(02)00098-6","article-title":"The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides","volume":"39","author":"Goldberg","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1038\/ki.2011.502_bb0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2003.11.004","article-title":"Proteasome and peptidase function in MHC-class-I-mediated antigen presentation","volume":"16","author":"Kloetzel","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/ki.2011.502_bb0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"key":"10.1038\/ki.2011.502_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrm1049","article-title":"How the ubiquitin-proteasome system controls transcription","volume":"4","author":"Muratani","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/ki.2011.502_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O","article-title":"Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators","volume":"187","author":"Yew","year":"2001","journal-title":"J Cell Physiol"},{"key":"10.1038\/ki.2011.502_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10495-005-3088-0","article-title":"Role of the unfolded protein response in cell death","volume":"11","author":"Kim","year":"2006","journal-title":"Apoptosis"},{"key":"10.1038\/ki.2011.502_bb0085","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhbitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1038\/ki.2011.502_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/187153007780059397","article-title":"Use of systemic proteasome inhibition as an immune-modulating agent in disease","volume":"7","author":"Mattingly","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1038\/ki.2011.502_bb0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00007890-200107270-00005","article-title":"A proteasome inhibitor effectively prevents mouse heart allograft rejection","volume":"72","author":"Luo","year":"2001","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0100","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/ki.2011.502_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/jaut.2000.0370","article-title":"Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519","volume":"14","author":"Vanderlugt","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1038\/ki.2011.502_bb0110","doi-asserted-by":"crossref","first-page":"15671","DOI":"10.1073\/pnas.95.26.15671","article-title":"Role of the proteasome and NK-\u03baB in streptococcal cell wall-induced polyarthritis","volume":"95","author":"Palombella","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2011.502_bb0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.TP.0000128855.10397.DB","article-title":"Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection","volume":"78","author":"Wu","year":"2004","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0120","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/ki.2010.15","article-title":"Immunoproteasome beta subunit 10 is increased in chronic antibody mediated rejection","volume":"77","author":"Ashton-Chess","year":"2010","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.502_bb0125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.humimm.2005.01.032","article-title":"Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin","volume":"66","author":"Zachary","year":"2005","journal-title":"Hum Immunol"},{"key":"10.1038\/ki.2011.502_bb0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1600-6143.2009.02968.x","article-title":"Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies","volume":"10","author":"Sberro-Soussan","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0140","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2009.02813.x","article-title":"Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies","volume":"9","author":"Loupy","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0145","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/j.1600-6143.2009.02701.x","article-title":"Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations","volume":"9","author":"Kraus","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0150","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1600-6143.2006.01657.x","article-title":"Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts","volume":"7","author":"Hass","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0155","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/TP.0b013e318218e901","article-title":"Proteasome inhibitor-based antihumoral therapy: differential response in early vs. late antibody mediated rejection","volume":"91","author":"Walsh","year":"2011","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0160","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2011.502_bb0165","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/TP.0b013e3181fdd9b0","article-title":"The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation","volume":"90","author":"Flechner","year":"2010","journal-title":"Transplantation"},{"issue":"s4","key":"10.1038\/ki.2011.502_bb0170","first-page":"83","article-title":"Proteasome inhibitor therapy for antibody mediated rejection: initial report from a multicenter collaborative","volume":"10","author":"Woodle","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0175","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0180","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"Am J Tranplant"},{"key":"10.1038\/ki.2011.502_bb0185","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injectiion in the treatment of myltiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"s4","key":"10.1038\/ki.2011.502_bb0190","first-page":"44","article-title":"Depletion of alloantibody-secreting plasma cells by proteasome inhibition improves desensitization","volume":"10","author":"Raghavaiah","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1038\/ki.2011.502_bb0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/TP.0b013e3181c280f9","article-title":"Acute humoral rejection in a lung recipient: reversion with bortezomib","volume":"89","author":"Neumann","year":"2010","journal-title":"Transplantation"},{"key":"10.1038\/ki.2011.502_bb0205","series-title":"Clin Transpl","first-page":"443","article-title":"Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients","author":"Govil","year":"2010"},{"issue":"Suppl 4","key":"10.1038\/ki.2011.502_bb0210","first-page":"93","article-title":"Proteasome inhibitor-based therapy for antibody mediated rejection in pediatric heart transplantation","volume":"10","author":"Morrow","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2011.502_bb0215","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1600-6143.2011.03526.x","article-title":"Regulatory approval for new antihumoral therapies: addressing the barriers","volume":"11","author":"Woodle","year":"2011","journal-title":"Am J Transplant"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815552204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815552204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T19:16:45Z","timestamp":1561317405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815552204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0085253815552204"],"URL":"https:\/\/doi.org\/10.1038\/ki.2011.502","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}